vTv Therapeutics Inc. (VTVT) Financials

VTVT

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$27.0M -46.1% YoY

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$25.3M +0.2% YoY

Market Cap $119.9M as of Oct 6, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.5x on $78.6M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VTVT SEC filings page.

vTv Therapeutics Inc. (VTVT) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VTVT FY2025 2026-10-03

Operations consume cash before commercial revenue is established, while financing has rebuilt the balance sheet rather than the business funding itself.

In FY2024, operating cash outflow was $25.3M against a net loss of $18.5M, reversing FY2022's narrower cash outflow relative to its loss. That widening gap means reported expenses were not the only drain on resources, making cash conversion more demanding than the income statement alone suggests.

FY2024 R&D and selling costs totaled $25.2M against just $1.0M of revenue, showing a development-stage cost structure whose spending is far ahead of commercial sales. With no meaningful gross-profit data, operating expenses—not product margin—are the clearest view of how the business currently operates.

A $52.6M financing inflow in FY2024 coincided with positive equity of $12.2M, indicating that balance-sheet improvement was financing-led rather than generated by operations. The current ratio reached 7.3x, while the supplied liquidity comparison equaled 42.3 months of the latest annual operating outflow; that describes funding relative to a past outflow, not operating self-sufficiency.

Financial Health Signals

Financial health score not available

vTv Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.35

vTv Therapeutics Inc. scores -2.35, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($119.9M) relative to total liabilities ($25.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/6

vTv Therapeutics Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

vTv Therapeutics Inc. reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

vTv Therapeutics Inc. reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

QoQ-100.0%

vTv Therapeutics Inc. generated $0 in revenue in Q2 2026. Against the prior quarter it is down 100.0%.

EBITDA

-$13.9M

YoY-80.5%

QoQ-159.9%

vTv Therapeutics Inc.'s EBITDA was -$13.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 80.5% from the same quarter a year earlier. Against the prior quarter it is down 159.9%.

Net Income

-$13.1M

YoY-115.9%

QoQ-154.1%

vTv Therapeutics Inc. reported -$13.1M in net income in Q2 2026. This represents a decrease of 115.9% from the same quarter a year earlier. Against the prior quarter it is down 154.1%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$86.6M

YoY+234.2%

QoQ-11.7%

5Y CAGR+51.6%

10Y CAGR+3.1%

vTv Therapeutics Inc. held $86.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Shares Outstanding

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-16.6%

YoY+202.3pp

QoQ-43.4pp

vTv Therapeutics Inc.'s ROE was -16.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 202.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 43.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$8.8M

YoY+113.7%

QoQ-2.3%

vTv Therapeutics Inc. invested $8.8M in research and development in Q2 2026. This represents an increase of 113.7% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

VTVT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	$0-100.0%	$1.0M	$0-100.0%	$2.0M-49.6%	$4.0M-37.6%	$6.4M+132.1%	$2.8M-77.8%	$12.4M+4172.9%	$291K-54.1%	$634K+22.2%	$519K-66.5%	$1.5M+58.7%	$976K
R&D Expenses	N/A	$17.9M+54.7%	$11.5M-15.1%	$13.6M+10.0%	$12.4M-7.3%	$13.3M+21.0%	$11.0M-27.1%	$15.1M-34.4%	$23.0M-41.9%	$39.6M-11.8%	$45.0M+65.0%	$27.2M+56.7%	$17.4M-22.0%	$22.3M
SG&A Expenses	N/A	$14.9M+9.5%	$13.7M+14.6%	$11.9M-2.4%	$12.2M-1.2%	$12.3M+70.2%	$7.3M-15.1%	$8.5M-7.4%	$9.2M-18.6%	$11.3M+14.4%	$9.9M+9.1%	$9.1M-22.5%	$11.7M+3.0%	$11.4M
Operating Income	N/A	-$32.8M-35.7%	-$24.2M+5.2%	-$25.5M-13.1%	-$22.5M-4.1%	-$21.7M-82.8%	-$11.9M+43.3%	-$20.9M-5.4%	-$19.8M+60.9%	-$50.7M+7.9%	-$55.0M-44.3%	-$38.1M-32.0%	-$28.9M+19.4%	-$35.8M
EBITDA	N/A	-$32.8M-36.1%	-$24.1M+5.2%	-$25.4M-13.2%	-$22.4M-4.1%	-$21.6M-83.5%	-$11.8M+43.6%	-$20.9M-6.4%	-$19.6M+61.2%	-$50.5M+7.8%	-$54.8M-45.5%	-$37.6M-34.3%	-$28.0M+19.3%	-$34.7M
Interest Expense	N/A	$6K	$0-100.0%	$13K-13.3%	$15K+25.0%	$12K-98.3%	$692K-62.1%	$1.8M-44.5%	$3.3M+6.4%	$3.1M+676.9%	$398K+268.5%	$108K-62.2%	$286K-39.9%	$476K
Income Tax	N/A	$0-100.0%	$100K	$0-100.0%	$200K+73.9%	$115K	$0-100.0%	$100K-50.0%	$200K-75.0%	$800K	$0	$0	$0	N/A
Net Income	N/A	-$27.0M-46.1%	-$18.5M+8.8%	-$20.3M-5.7%	-$19.2M-47.6%	-$13.0M-52.8%	-$8.5M+34.8%	-$13.0M-64.9%	-$7.9M+51.0%	-$16.1M+1.3%	-$16.4M+40.5%	-$27.5M+23.8%	-$36.1M+25.1%	-$48.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$36.8M	N/A	$0	$0	$0-100.0%	N/A	$0
R&D Expenses	$8.8M+113.7%	$9.0M+217.2%	N/A	$7.0M+117.7%	$4.1M+19.3%	$2.8M+6.8%	N/A	$3.2M+14.2%
SG&A Expenses	$5.2M+42.6%	$4.6M+25.2%	N/A	$3.7M+12.1%	$3.6M-2.6%	$3.7M-7.7%	N/A	$3.3M+29.0%
Operating Income	-$13.9M-80.4%	$23.3M+457.7%	N/A	-$10.7M-64.4%	-$7.7M-7.9%	-$6.5M-15.6%	N/A	-$6.5M-21.2%
EBITDA	-$13.9M-80.5%	$23.3M+458.2%	N/A	-$10.7M-65.0%	-$7.7M-8.2%	-$6.5M-15.9%	N/A	-$6.5M-21.3%
Interest Expense	N/A	N/A	N/A	$5K	N/A	N/A	N/A	$0-100.0%
Income Tax	$0	$0	N/A	$0	$0	$0-100.0%	N/A	$0
Net Income	-$13.1M-115.9%	$24.1M+574.0%	N/A	-$8.7M-81.9%	-$6.0M-16.7%	-$5.1M-4.7%	N/A	-$4.8M+28.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

VTVT Balance Sheet

VTVT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$89.9M+134.9%	$38.3M+247.3%	$11.0M-66.9%	$33.2M+30.5%	$25.5M+72.2%	$14.8M+59.6%	$9.3M+8.3%	$8.6M-69.3%	$27.9M-48.8%	$54.5M-40.5%	$91.5M+606.8%	$13.0M	N/A
Current Assets	$89.9M+135.9%	$38.1M+257.6%	$10.7M-60.7%	$27.1M+73.4%	$15.6M+116.5%	$7.2M+154.2%	$2.8M-18.3%	$3.5M-82.9%	$20.4M-60.9%	$52.1M-41.6%	$89.2M+5436.1%	$1.6M	N/A
Cash & Equivalents	$88.9M+142.0%	$36.7M+289.0%	$9.4M-22.1%	$12.1M-9.6%	$13.4M+133.4%	$5.7M+223.4%	$1.8M+5.6%	$1.7M-85.7%	$11.8M-77.2%	$51.5M-41.5%	$88.0M+6258.6%	$1.4M+27.1%	$1.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	$62K-39.2%	$102K-41.0%	$173K+203.5%	$57K-63.9%	$158K+3060.0%	$5K	$0-100.0%	$8.0M	$0-100.0%	$69K	N/A	N/A
Long-Term Investments	$0	$0	$0-100.0%	$5.6M-39.1%	$9.2M+36.4%	$6.7M+171.2%	$2.5M0.0%	$2.5M0.0%	$2.5M	$0	$0	$0	$0
Total Liabilities	$25.5M+6.2%	$24.0M-32.9%	$35.7M-18.8%	$44.0M+24.9%	$35.2M-62.9%	$94.9M+62.8%	$58.3M-36.2%	$91.4M-48.9%	$179.0M+23.1%	$145.4M-14.2%	$169.5M-66.9%	$511.8M	N/A
Current Liabilities	$6.6M+27.8%	$5.2M-51.1%	$10.6M+37.8%	$7.7M-9.3%	$8.5M+33.0%	$6.4M-52.2%	$13.4M-29.0%	$18.8M-30.0%	$26.9M+135.5%	$11.4M+48.0%	$7.7M+12.6%	$6.9M	N/A
Non-Current Liabilities	$18.8M+0.3%	$18.8M-25.2%	$25.1M-30.9%	$36.3M+35.8%	$26.7M-69.8%	$88.5M+97.1%	$44.9M-38.1%	$72.6M-52.3%	$152.0M+13.5%	$134.0M-17.2%	$161.8M-68.0%	$504.9M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$5.0M-66.6%	$15.1M	N/A	$11.1M	N/A	$2.1M	N/A
Total Equity	$64.4M+428.2%	$12.2M+149.4%	-$24.7M-129.8%	-$10.7M-10.3%	-$9.7M+87.8%	-$80.1M-63.4%	-$49.0M+40.8%	-$82.9M+45.1%	-$151.0M-66.1%	-$90.9M-16.6%	-$78.0M+84.4%	-$498.8M-64.2%	-$303.7M
Retained Earnings	-$326.7M-9.0%	-$299.7M-6.6%	-$281.0M-5.8%	-$265.5M-6.7%	-$248.8M+14.2%	-$290.0M-24.2%	-$233.5M+0.2%	-$233.9M+16.2%	-$279.1M-29.5%	-$215.5M-10.0%	-$196.0M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$87.6M+231.2%	$98.8M+208.5%	$89.9M+134.9%	$99.5M+130.5%	$26.4M-43.1%	$32.0M-40.9%	$38.3M+247.3%	$43.2M+189.2%
Current Assets	$87.6M+232.1%	$98.8M+209.6%	$89.9M+135.9%	$99.5M+131.5%	$26.4M-42.9%	$31.9M-40.8%	$38.1M+257.6%	$43.0M+324.3%
Cash & Equivalents	$86.6M+234.2%	$98.1M+215.8%	$88.9M+142.0%	$98.5M+137.0%	$25.9M-43.1%	$31.1M-40.6%	$36.7M+289.0%	$41.6M+404.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$62K-39.2%	$242K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Liabilities	$9.0M-62.7%	$8.9M-61.7%	$25.5M+6.2%	$29.0M+14.7%	$24.0M-7.6%	$23.1M-18.0%	$24.0M-32.9%	$25.3M-37.1%
Current Liabilities	$7.0M+32.5%	$6.9M+59.4%	$6.6M+27.8%	$10.2M+58.2%	$5.3M-24.2%	$4.3M-51.6%	$5.2M-51.1%	$6.4M-37.5%
Non-Current Liabilities	$1.9M-89.6%	$2.0M-89.5%	$18.8M+0.3%	$18.8M-0.2%	$18.7M-1.5%	$18.8M-2.4%	$18.8M-25.2%	$18.8M-37.0%
Total Equity	$78.6M+2746.9%	$90.0M+1035.8%	$64.4M+428.2%	$70.5M+370.0%	$2.8M-83.2%	$7.9M-61.9%	$12.2M+149.4%	$15.0M+159.5%
Retained Earnings	-$315.6M-1.5%	-$302.6M+0.7%	-$326.7M-9.0%	-$319.6M-7.9%	-$310.9M-6.7%	-$304.8M-6.5%	-$299.7M-6.6%	-$296.1M-5.3%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

VTVT Cash Flow Statement

VTVT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$16.8M	-$25.3M+0.2%	-$25.3M-32.6%	-$19.1M-19.1%	-$16.0M+17.0%	-$19.3M-7.3%	-$18.0M+21.8%	-$23.0M+14.3%	-$26.9M+39.7%	-$44.6M+7.6%	-$48.2M-30.5%	-$36.9M-20.0%	-$30.8M+26.2%	-$41.7M
Depreciation & Amortization	N/A	$16K-82.0%	$89K-1.1%	$90K-2.2%	$92K+3.4%	$89K-5.3%	$94K+141.0%	$39K-82.1%	$218K+10.7%	$197K-25.7%	$265K-47.1%	$501K-42.0%	$864K-20.4%	$1.1M
Stock-Based Compensation	N/A	$3.8M+36.9%	$2.8M+74.7%	$1.6M+24.1%	$1.3M-46.0%	$2.4M+133.5%	$1.0M-33.5%	$1.5M-43.3%	$2.7M-26.6%	$3.6M+38.0%	$2.6M+207.5%	$859K	N/A	N/A
Capital Expenditures	N/A	N/A	$0	$0-100.0%	$21K	$0	$0-100.0%	$70K+1300.0%	$5K-91.2%	$57K-34.5%	$87K-16.3%	$104K+215.2%	$33K-81.8%	$181K
Free Cash Flow	N/A	N/A	-$25.3M-32.6%	-$19.1M-18.9%	-$16.0M+16.9%	-$19.3M-7.3%	-$18.0M+22.0%	-$23.1M+14.0%	-$26.9M+39.8%	-$44.6M+7.6%	-$48.3M-30.4%	-$37.0M-20.2%	-$30.8M+26.4%	-$41.9M
Investing Cash Flow	N/A	$0	$0-100.0%	$4.4M+21071.4%	-$21K	$0	$0-100.0%	$242K+3357.1%	$7K+128.0%	-$25K+69.9%	-$83K	N/A	N/A	N/A
Financing Cash Flow	N/A	$77.4M+47.2%	$52.6M+338.5%	$12.0M-18.7%	$14.8M-45.3%	$27.0M+38.6%	$19.5M-14.9%	$22.9M+37.7%	$16.6M+121.5%	$7.5M-36.4%	$11.8M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$11.4M-124.6%	$9.2M+261.0%	-$9.3M-91.7%	-$5.2M+18.6%	-$5.1M+24.3%	-$5.7M+22.5%	-$4.8M-65.6%	-$6.4M-32.8%
Depreciation & Amortization	$1K-66.7%	$1K-88.9%	$2K-90.9%	$2K-90.9%	$3K-87.0%	$9K-59.1%	$22K-4.3%	$22K0.0%
Stock-Based Compensation	$1.7M+85.7%	$1.4M+70.7%	N/A	$1.0M+18.1%	$930K+8.3%	$813K+269.5%	N/A	$853K+97.0%
Financing Cash Flow	N/A	N/A	-$321K	$77.8M+3058.9%	-$42K	$0-100.0%	$0+100.0%	$2.5M+420.7%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

VTVT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	N/A	-2377.6%	N/A	-1116.9%	-540.9%	-184.8%	-755.9%	-159.4%	-17416.5%	-8678.2%	-7349.1%	-1865.5%	-3671.4%
Net Margin	N/A	-1815.3%	N/A	-949.6%	-324.3%	-132.5%	-471.9%	-63.6%	-5547.8%	-2579.2%	-5298.3%	-2330.6%	-4938.8%
Return on Equity	-41.9%+109.5pp	-151.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-30.0%+18.3pp	-48.3%+135.5pp	-183.8%-126.1pp	-57.7%-6.7pp	-51.0%+6.5pp	-57.5%+83.3pp	-140.8%-48.3pp	-92.4%-34.6pp	-57.8%-27.8pp	-30.0%0.0pp	-30.0%+248.7pp	-278.8%	N/A
Current Ratio	13.54+6.2x	7.34+6.3x	1.00-2.5x	3.52+1.7x	1.84+0.7x	1.13+0.9x	0.210.0x	0.18-0.6x	0.76-3.8x	4.56-7.0x	11.54+11.3x	0.23	N/A
Debt-to-Equity	0.40-1.6x	1.96	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.000.0x	0.030.0x	0.00-0.1x	0.06-0.1x	0.16-0.3x	0.43+0.1x	0.30-1.2x	1.45+1.4x	0.010.0x	0.010.0x	0.01-0.1x	0.12	N/A
FCF Margin	N/A	-2488.4%	N/A	-795.0%	-482.1%	-280.6%	-835.3%	-216.0%	-15332.3%	-7617.7%	-7138.7%	-1989.2%	-4289.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	63.1%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	65.5%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-16.6%+202.3pp	26.8%+91.1pp	N/A	-12.3%+19.5pp	-218.9%-187.5pp	-64.3%-40.9pp	N/A	-31.9%
Return on Assets	-14.9%+8.0pp	24.4%+40.3pp	N/A	-8.7%+2.3pp	-22.9%-11.7pp	-15.9%-6.9pp	N/A	-11.1%+33.5pp
Current Ratio	12.48+7.5x	14.36+7.0x	13.54+6.2x	9.79+3.1x	4.98-1.6x	7.39+1.4x	7.34+6.3x	6.69+5.7x
Debt-to-Equity	0.11-8.6x	0.10-2.8x	0.40-1.6x	0.41-1.3x	8.70+7.1x	2.92+1.6x	1.96	1.68
Asset Turnover	0.000.0x	0.37+0.4x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
vTv Therapeutics Inc. VTVT	FY2025	$0	-$27.0M	N/A	$119.9M	—
Serina Therapeutics, Inc. SER	FY2025	$130K	-$19.2M	N/A	$49.8M	—
Relmada Therapeutics, Inc. RLMD	FY2025	N/A	$0	N/A	$384.0M	—
PDS Biotechnology Corporation PDSB	FY2025	N/A	-$34.5M	N/A	$54.2M	—
PolyPid Ltd. PYPD	FY2025	N/A	-$34.2M	N/A	$105.4M	—
Jupiter Neurosciences, Inc. JUNS	FY2025	$22K	-$8.6M	N/A	$3.4M	—

Where vTv Therapeutics Inc. Ranks

Frequently Asked Questions

What is vTv Therapeutics Inc.'s annual revenue?

vTv Therapeutics Inc. (VTVT) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is vTv Therapeutics Inc.'s revenue growing?

vTv Therapeutics Inc. (VTVT) revenue declined by 100.0% year-over-year, from $1.0M to $0 in fiscal year 2025.

Is vTv Therapeutics Inc. profitable?

No, vTv Therapeutics Inc. (VTVT) reported a net income of -$27.0M in fiscal year 2025.

What is vTv Therapeutics Inc.'s EBITDA?

vTv Therapeutics Inc. (VTVT) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is vTv Therapeutics Inc.'s return on equity (ROE)?

vTv Therapeutics Inc. (VTVT) has a return on equity of -41.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is vTv Therapeutics Inc.'s operating cash flow?

vTv Therapeutics Inc. (VTVT) recorded an outflow of $25.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are vTv Therapeutics Inc.'s total assets?

vTv Therapeutics Inc. (VTVT) had $89.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does vTv Therapeutics Inc. spend on research and development?

vTv Therapeutics Inc. (VTVT) invested $17.9M in research and development during fiscal year 2025.

What is vTv Therapeutics Inc.'s current ratio?

vTv Therapeutics Inc. (VTVT) had a current ratio of 13.54 as of fiscal year 2025, which is generally considered healthy.

What is vTv Therapeutics Inc.'s debt-to-equity ratio?

vTv Therapeutics Inc. (VTVT) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is vTv Therapeutics Inc.'s return on assets (ROA)?

vTv Therapeutics Inc. (VTVT) had a return on assets of -30.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is vTv Therapeutics Inc.'s P/E ratio?

vTv Therapeutics Inc. (VTVT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $119.9M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is vTv Therapeutics Inc.'s price-to-sales ratio?

vTv Therapeutics Inc. (VTVT) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $119.9M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does vTv Therapeutics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, vTv Therapeutics Inc. (VTVT) held $88.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.3M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is vTv Therapeutics Inc.'s Altman Z-Score?

vTv Therapeutics Inc. (VTVT) has an Altman Z-Score of -2.35, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is vTv Therapeutics Inc.'s Piotroski F-Score?

vTv Therapeutics Inc. (VTVT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are vTv Therapeutics Inc.'s earnings high quality?

vTv Therapeutics Inc. (VTVT) reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can vTv Therapeutics Inc. cover its interest payments?

vTv Therapeutics Inc. (VTVT) reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.